RxDoctor Payments Data

Swati Patel, APRN

Adult Health · Vernon, CTNPI 1336317478

Payments from drug & device makers

$806in general payments, 2019–2025

Across 30 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$267
  • Viiv Healthcare Company$141
  • Dexcom, Inc.$114
  • AbbVie$113
  • Exact Sciences$69
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$806 in reported general payments places this provider in the 65th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,244
Medicare patients
128
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$37,166
EliquisApixaban28$30,633
TrulicityDulaglutide25$29,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,149
JanuviaSitagliptin Phosphate14$9,320
Fluticasone-VilanterolFluticasone/Vilanterol15$6,232
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,570
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,556
Insulin Lispro Kwikpen U-100Insulin Lispro21$3,494
Albuterol Sulfate HfaAlbuterol Sulfate95$2,429
Levemir FlexpenInsulin Detemir13$2,384
SynthroidLevothyroxine Sodium22$1,982
Atorvastatin Calcium218$1,678
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,559
Wixela InhubFluticasone Propion/Salmeterol15$1,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$267$21,14932 claims
AbbVieSynthroid$113$1,98222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 418 adult health providers in Connecticut.

Other adult health in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →